Construction of a prognostic model based on disulfidptosis-related genes and identification of CCNA2 as a novel biomarker for hepatocellular carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies a 5-gene signature predicting hepatocellular carcinoma (HCC) outcomes and highlights Cyclin A2 (CCNA2) as a potential biomarker. Targeting CCNA2 may inhibit HCC proliferation and migration.
Area Of Science
- Oncology
- Cell Biology
- Genomics
Background
- Disulfidptosis is an emerging cell death pathway with limited research in cancer.
- Understanding disulfidptosis-related genes (DRGs) in hepatocellular carcinoma (HCC) is crucial.
Purpose Of The Study
- To develop a prognostic signature for HCC based on DRGs.
- To investigate the role of Cyclin A2 (CCNA2) in HCC progression.
Main Methods
- Utilized TCGA and GEO data to analyze 24 DRGs.
- Constructed a 5-DRG prognostic signature using regression analyses.
- Validated CCNA2's role through IHC, qRT-PCR, western blot, and cell-based assays.
Main Results
- Identified three HCC patterns; pattern B showed poor survival.
- Developed a 5-DRG signature (STC2, PBK, CCNA2, SERPINE1, SLC6A1).
- CCNA2 inhibition suppressed proliferation and migration, promoting apoptosis and downregulating EMT markers in HCC cells.
Conclusions
- The 5-DRG signature predicts HCC outcomes and immune microenvironment characteristics.
- CCNA2 shows potential as a novel biomarker for HCC treatment strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.